The Study
PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis
This study looks at a few small reports together and finds that when people who had heart transplants took PCSK9 drugs, their bad cholesterol usually went down. But we can't be sure the drug caused the drop, because the original studies might not have been fair tests — like comparing the drug to a fake pill or using random assignment.
Analysis score
Maximum 100 for a systematic review with meta-analysis.
Where the score came from
Some heart transplant patients can't take common cholesterol pills called statins. This study looked at whether a newer type of medicine, called PCSK9 inhibitors, can help lower bad cholesterol in these patients.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 541 / 100
Quality score
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Key takeaways
Summary
Based on the study abstract and findings.
- 1This means the medicine might be safe and helpful for lowering cholesterol in heart transplant patients who can't take statins.
- 2The medicine lowered bad cholesterol by 82.61 mg/dL.
- 3No serious side effects were linked to it.
- 4Other medicines the patients take stayed at the same levels.
- 5Heart scans showed no worsening.
- 6No bad immune reactions happened in the first month.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Heart Failure Reviews
Year
2022
Authors
D. Jennings, L. Sultan, Jennifer Mingov, J. Choe, F. Latif, S. Restaino, K. Clerkin, M. Habal, P. Colombo, Melana Yuzefpulskaya, G. Sayer, N. Uriel, W. Baker
Related Content
Claims (6)
Adding PCSK9 drugs to cholesterol-lowering statins can slash bad cholesterol by as much as 81% in people with high cholesterol.
For people who've had a heart transplant and can't take cholesterol pills like statins, a newer medicine called a PCSK9 inhibitor might help lower their bad cholesterol by about 83 points over a year.
People who got a new heart and took a drug called a PCSK9 inhibitor didn’t have serious side effects from the medicine — in fact, none of the 97 patients studied had problems caused by the drug over nearly two years.
Heart transplant patients taking PCSK9 inhibitor drugs don’t seem to develop harmful immune reactions to their new heart in the first month, which means their body isn’t showing early signs of rejecting it.
If you've had a heart transplant and start taking a PCSK9 inhibitor for cholesterol, it probably won't mess with your anti-rejection medication levels.
For some people who've had a heart transplant, taking PCSK9 inhibitor drugs might help keep the inside of their heart's blood vessels from getting narrower over time.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.